Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.

N/ACompletedNCT07320781

Shaukat Khanum Memorial Cancer Hospital & Research Centre70 enrolled

Overview

This study evaluated the preemptive analgesic efficacy of Tapentadol in reducing peri operative analgesic requirements among patients undergoing breast cancer surgery.

A double blinded prospective RCT was conducted with 70 patients undergoing breast cancer surgery with 35 patients being studied with Administrated drug \& other 35 as placebo. Intraoperative \& postoperative morphine consumption was calculated and documented.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Breast Cancer

Interventions

TapentadolDRUG

75 mg oral tapentadol given 1 hour before surgery in control group and placebo tablet was given in Group B. Intraoperative and post operative morphine consumption and pain scores at 1,2,3,4 hours were calculated.

PlaceboOTHER

Placebo tablet was given in group B.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. 18-60 years 2. ASA 1,2,3 3. Patients scheduled for breast conservation surgery - Exclusion Criteria: 1. Patient refusal 2. CKD greater than 3 3. BMI greater than 35 4. Known drug allergy -

Locations (1)

SKMCH & RC Lahore

Lahore, Punjab Province, Pakistan

Outcomes

Primary Outcomes

Intraoperative and postoperative morphine consumption

During the course of surgery and up to 4 hours surgery Intraoperative and postoperative morphine consumption.

Time frame: During the course of surgery and up to 4 hours surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.